CRPA 1A2 TCR-based T-cell engager - Beijing Kerui Biotechnology
Alternative Names: CRPA-1A2Latest Information Update: 09 Aug 2024
At a glance
- Originator Beijing Kerui Biotechnology
- Class Antineoplastics; Immunoglobulin fragments; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours